Earnings Data
Report Date
Jul 29, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
3.23Last Year’s EPS
2.87Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: double-digit net operating EPS growth, strong year-over-year sales (notably +58% health net sales), solid investment yields and disciplined capital returns including an increased dividend and accelerated buybacks. Management provided constructive guidance and highlighted a meaningful Q3 remeasurement tailwind ($70M–$110M pre-tax). Challenges noted—elevated lapse rates, a decline in producing agent count at American Income, Q1 health seasonality, rising administrative expenses and an unrealized investment loss position—are being actively managed through compensation changes, AI/technology investments, rate increases in health and conservative investment/holding strategies. Overall, the positive results, strengthened guidance, and shareholder-friendly capital deployment outweigh the manageable operational headwinds described.Company Guidance
Strong Earnings and Operating EPS Growth
Net income of $271 million ($3.39 per share) in Q1 2026 versus $255 million ($3.01 per share) a year ago; net operating income per share of $3.43, an increase of 12% year-over-year (from $3.07).
Improved Book Value and Return on Equity
GAAP return on equity through March 31 of 17.9%; book value per share $77.30. Excluding AOCI, return on equity 14% and book value per share $98.56, up 12% year-over-year.
Premium Revenue and Underwriting Performance
Total premium revenue grew 6% in Q1; company expects ~7% premium growth for full year. Life premium revenue up 3% to $853 million and life underwriting margin up 3% to $349 million (life margin 41% in Q1). Health premium revenue up 13% to $417 million and health underwriting margin up 12% to $95 million (health margin ~23% in Q1).
Exceptional Sales Momentum in Health and Solid Life Sales
Total life net sales grew 6% and total health net sales grew 58% in Q1. Notable divisional performance: United American General Agency net health sales $62 million (up ~ $34 million year-over-year) and Family Heritage net health sales up 22% to $33 million.
Distribution Wins and Agency-Level Growth
American Income life premiums +5% to $459M and underwriting margin +7% to $209M; Liberty National life net sales +13% and average producing agent count +9% year-over-year; Family Heritage average producing agent count +10% and health premiums +10%.
Investments and Yield Profile
Invested assets $22 billion (including $19.1B fixed maturities). Earned yield on long-term invested assets 5.5% in Q1; fixed-maturity purchases in Q1 averaged 6.23% yield. Company expects full-year long-term investment yield 5.45%–5.50% and plans ~$1.1B–$1.2B in investments at an average yield of 6.3%–6.5%.
Capital Return and Liquidity Actions
During Q1 the company repurchased ~1.4 million shares for ~$205 million and returned ~$225 million to shareholders including ~$20 million in dividends. Increased annual dividend rate by 22% and raised full-year share repurchase range to $560M–$610M.
Strong Capital and Solvency Metrics
Consolidated RBC for U.S. insurance subsidiaries was 316% at year-end 2025, providing approximately $95 million of excess capital above the company's 300% minimum target; target consolidated RBC range 300%–320%.
Raised and Refined 2026 Guidance
Net operating diluted EPS guidance of $15.40–$15.90 for 2026 (approx. 8% growth at midpoint). Normalized EPS growth excluding assumption updates ~11% at midpoint; projected 3-year CAGR of normalized EPS ~11.5%. Company forecasts a pre-tax remeasurement benefit of $70M–$110M expected in Q3 (implying a one-quarter life margin of ~49%–54%).
Incremental Investment Income and Excess Investment Income Growth
Net investment income of $290 million (up 3% year-over-year) and excess investment income of $37 million (up ~$1 million year-over-year). Expected net investment income and required interest growth around 4% for full year, implying excess investment income growth of ~4%–4.5%.
DE:TMJ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:TMJ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 22, 2026 | €127.50 | €128.30 | +0.63% |
Feb 04, 2026 | €120.71 | €121.71 | +0.83% |
Oct 22, 2025 | €116.50 | €115.50 | -0.85% |
Jul 23, 2025 | €103.35 | €105.34 | +1.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Globe Life Inc. (DE:TMJ) report earnings?
Globe Life Inc. (DE:TMJ) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).
What is Globe Life Inc. (DE:TMJ) earnings time?
Globe Life Inc. (DE:TMJ) earnings time is at Jul 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Globe Life Inc. stock?
The P/E ratio of Globe Life is N/A.
What is DE:TMJ EPS forecast?
DE:TMJ EPS forecast for the fiscal quarter 2026 (Q2) is 3.23.